Clinical and Developmental Neuropsychology Research Group, Institute of Cognitive Neuroscience and Psychology, Research Centre for Natural Sciences, Budapest, Hungary.
Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary.
Int J Neuropsychopharmacol. 2024 Jul 1;27(7). doi: 10.1093/ijnp/pyae025.
A compelling hypothesis about attention-deficit/hyperactivity disorder (ADHD) etiopathogenesis is that the ADHD phenotype reflects a delay in cortical maturation. Slow-wave activity (SWA) of non-rapid eye movement (NREM) sleep electroencephalogram (EEG) is an electrophysiological index of sleep intensity reflecting cortical maturation. Available data on ADHD and SWA are conflicting, and developmental differences, or the effect of pharmacological treatment, are relatively unknown.
We examined, in samples (Mage = 16.4, SD = 1.2), of ever-medicated adolescents at risk for ADHD (n = 18; 72% boys), medication-naïve adolescents at risk for ADHD (n = 15, 67% boys), and adolescents not at risk for ADHD (n = 31, 61% boys) matched for chronological age and controlling for non-ADHD pharmacotherapy, whether ADHD pharmacotherapy modulates the association between NREM SWA and ADHD risk in home sleep.
Findings indicated medication-naïve adolescents at risk for ADHD exhibited greater first sleep cycle and entire night NREM SWA than both ever-medicated adolescents at risk for ADHD and adolescents not at risk for ADHD and no difference between ever-medicated, at-risk adolescents, and not at-risk adolescents.
Results support atypical cortical maturation in medication-naïve adolescents at risk for ADHD that appears to be normalized by ADHD pharmacotherapy in ever-medicated adolescents at risk for ADHD. Greater NREM SWA may reflect a compensatory mechanism in middle-later adolescents at risk for ADHD that normalizes an earlier occurring developmental delay.
关于注意力缺陷多动障碍(ADHD)发病机制的一个引人注目的假设是,ADHD 表型反映了皮质成熟的延迟。非快速眼动(NREM)睡眠脑电图(EEG)的慢波活动(SWA)是反映皮质成熟的睡眠强度的电生理指标。关于 ADHD 和 SWA 的现有数据相互矛盾,且发育差异或药物治疗的影响相对未知。
我们在曾接受过 ADHD 药物治疗的风险青少年(n=18;72%男孩)、未接受过 ADHD 药物治疗的风险青少年(n=15;67%男孩)和未患 ADHD 的风险青少年(n=31;61%男孩)样本中进行了检查,这些样本的年龄均为 16.4 岁(SD=1.2),按年龄与未患 ADHD 的风险青少年相匹配,并控制了非 ADHD 药物治疗,以检验 ADHD 药物治疗是否调节了家庭睡眠中 NREM SWA 与 ADHD 风险之间的关联。
研究结果表明,未接受过 ADHD 药物治疗的风险青少年在第一个睡眠周期和整个夜间的 NREM SWA 上均高于曾接受过 ADHD 药物治疗的风险青少年和未患 ADHD 的风险青少年,而曾接受过 ADHD 药物治疗的风险青少年与未患 ADHD 的风险青少年之间则无差异。
结果支持未接受过 ADHD 药物治疗的风险青少年的皮质成熟异常,而 ADHD 药物治疗似乎可使曾接受过 ADHD 药物治疗的风险青少年的皮质成熟恢复正常。较大的 NREM SWA 可能反映了 ADHD 风险中、后期青少年的代偿机制,使更早发生的发育延迟恢复正常。